Article info
PDFResearch
Original article
Phenotypical difference in deamination of cytarabine is not evident in induction therapy for acute myeloid leukaemia
- Correspondence to Professor Per Hartvig Honoré, Faculty of Health and Medical Sciences, Department of Drug design and Pharmacology, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark; peh{at}sund.ku.dk
Citation
Phenotypical difference in deamination of cytarabine is not evident in induction therapy for acute myeloid leukaemia
Publication history
- Received December 12, 2012
- Accepted February 11, 2013
- First published March 1, 2013.
Online issue publication
May 13, 2016
Article Versions
- Previous version (13 May 2016).
- Previous version (13 May 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions